Arbutus Q2 net loss $19.8M; cuts workforce 40%, extends cash runway to Q4 2026

Arbutus Biopharma Corp

2024-Q2 EPS reported -$0.21 revenue$3,258,000

Net loss of $19.8M ($0.11 loss per share) vs $17.1M loss prior year; revenue $1.7M down from $4.7M.
Workforce reduction of 40% (discontinuing HBV discovery); one-time restructuring charge $3-4M in Q3.
Cash, cash equivalents & investments $148.5M; cash runway extended into Q4 2026 (2024 cash burn guidance $63-67M).
IM-PROVE I data: 33% of patients achieved undetectable HBsAg; 67% for those with baseline HBsAg <1000 IU/mL.
LNP litigation vs Moderna trial set for April 21, 2025; Pfizer/BioNTech ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.